Logo image
Management of Helicobacter pylori infection in paediatric patients in Europe: results from the EuroPedHp Registry
Journal article   Open access   Peer reviewed

Management of Helicobacter pylori infection in paediatric patients in Europe: results from the EuroPedHp Registry

Thu Giang Le Thi, Katharina Werkstetter, Kallirroi Kotilea, Patrick Bontems, José Cabral, Maria Luz Cilleruelo Pascual, Michal Kori, Josefa Barrio, Matjaž Homan, Nicolas Kalach, …
Infection, Vol.51(4), pp.921-934
08/01/2023
DOI: 10.1007/s15010-022-01948-y
PMID: 36329342
url
https://doi.org/10.1007/s15010-022-01948-yView
Published (Version of record) Open Access

Abstract

The EuroPedHp-registry aims to monitor guideline-conform management, antibiotic resistance, and eradication success of 2-week triple therapy tailored to antibiotic susceptibility (TTT) in Helicobacter pylori-infected children. From 2017 to 2020, 30 centres from 17 European countries reported anonymized demographic, clinical, antibiotic susceptibility, treatment, and follow-up data. Multivariable logistic regression identified factors associated with treatment failure. Of 1605 patients, 873 had follow-up data (53.2% female, median age 13.0 years, 7.5% with ulcer), thereof 741 (85%) treatment naïve (group A) and 132 (15%) after failed therapy (group B). Resistance to metronidazole was present in 21% (A: 17.7%, B: 40.2%), clarithromycin in 28.8% (A: 25%, B: 51.4%), and both in 7.1% (A: 3.8%, B: 26.5%). The majority received 2-week tailored triple therapy combining proton pump inhibitor (PPI), amoxicillin with clarithromycin (PAC) or metronidazole (PAM). Dosing was lower than recommended for PPI (A: 49%, B: 41%) and amoxicillin (A: 6%, B: 56%). In treatment naïve patients, eradication reached 90% (n = 503, 95% CI 87-93%) and 93% in compliant children (n = 447, 95% CI 90-95%). Tailored triple therapy cured 59% patients after failed therapy (n = 69, 95% CI 48-71%). Treatment failure was associated with PAM in single clarithromycin resistance (OR = 2.47, 95% CI 1.10-5.53), with PAC in single metronidazole resistance (OR = 3.44, 95% CI 1.47-8.08), and with low compliance (OR = 5.89, 95% CI 2.49-13.95). Guideline-conform 2-weeks therapy with PPI, amoxicillin, clarithromycin or metronidazole tailored to antibiotic susceptibility achieves primary eradication of ≥ 90%. Higher failure rates in single-resistant strains despite tailored treatment indicate missed resistance by sampling error.
Europe Adolescent Amoxicillin - adverse effects Amoxicillin - therapeutic use Anti-Bacterial Agents - pharmacology Child Clarithromycin - pharmacology Clarithromycin - therapeutic use Drug Therapy, Combination Female Helicobacter Infections - chemically induced Helicobacter Infections - drug therapy Helicobacter pylori Humans Male Metronidazole - therapeutic use Proton Pump Inhibitors - adverse effects Proton Pump Inhibitors - therapeutic use Treatment Outcome

Details

Metrics

Logo image